Wan · FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003 · Controlled animal experiment · n=?

Intermittent fasting and dietary supplementation with 2-deoxy-D-glucose improve functional and metabolic cardiovascular risk factors in rats.

Cited 143 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Animal research with no human data

PubMed 12709404 · doi:10.1096/fj.02-0996fje · record verified 2026-08-30

What was done

Four-month-old male rats were implanted with telemetry probes to continuously record heart rate, blood pressure, physical activity, and body temperature. They were maintained for 6 months on one of three dietary regimens: ad libitum feeding, intermittent fasting (IF), or dietary supplementation with 2-deoxy-D-glucose (2DG, a non-metabolizable glucose analog). Serum glucose, insulin, adrenocorticotropin, and corticosterone levels were also measured.

What was found

Rats on the IF regimen consumed 30% less food over time and had reduced body weights compared to ad libitum controls, whereas 2DG-supplemented rats maintained food intake and body weight. Both IF and 2DG groups showed significant reductions in heart rate and blood pressure within 1 month that persisted throughout the 6 months. Body temperature decreased significantly in the IF group but not the 2DG group. Both IF and 2DG significantly decreased serum glucose and insulin levels, and both significantly increased plasma adrenocorticotropin and corticosterone levels. The abstract reports no exact numerical values, variance, or p-values.

Why it matters

This study suggests that intermittent fasting improves metabolic and cardiovascular risk factors in rats, and that a chemical glycolytic inhibitor (2DG) can mimic these hemodynamic and insulin-sensitizing benefits without requiring caloric restriction or weight loss.

Limits

The study was conducted exclusively in male rats, limiting direct applicability to humans. The abstract omits sample sizes (n) and all exact quantitative values, baseline measures, and effect sizes. Long-term safety and tolerability of 2DG were not fully characterized beyond the measured endpoints.

Cited by